# A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

> **NCT02213263** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 394 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** PF-05280586
- **BIOLOGICAL:** MabThera®

## Key facts

- **NCT ID:** NCT02213263
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-30
- **Primary completion:** 2017-10-23
- **Final completion:** 2018-04-19
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2019-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213263, "A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02213263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*